Facebook
Twitter
Telegram
Report an ErrorAziyo Biologics Balance Sheet 2011-2024 | AZYO
Annual Balance Sheet Aziyo Biologics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
1.36 M | 7.5 M | -11.9 M | -8.52 M | 23 M | 17.1 M | - | - | - | - | - | - | - |
Long Term Debt |
20.4 M | 24.3 M | 10.4 M | 17.8 M | 19.6 M | 16.5 M | - | - | - | - | - | - | - |
Long Term Debt Current |
275 K | 232 K | 8.06 M | 6.31 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 35.2 M | 81.6 M | 77.8 M | - | - | - | - | - | - | - |
Total Current Liabilities |
43 M | 42.6 M | 26 M | 26.8 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
82 M | 73.9 M | 53.6 M | 62 M | 99.9 M | 91.1 M | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | 533 K | 650 K | 648 K | - | - | - | - | - | - | - |
Retained Earnings |
-176 M | -138 M | -105 M | - | - | - | - | - | - | - | - | - | - |
Total Assets |
43.4 M | 68.8 M | 67.2 M | 82.8 M | 44.8 M | 47.7 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
19.3 M | 17 M | 30.4 M | 39.2 M | 2.59 M | - | - | - | - | - | - | - | - |
Book Value |
-38.6 M | -5.03 M | 13.5 M | 20.8 M | -55.1 M | -43.4 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
-38.6 M | -5.03 M | 13.5 M | 20.8 M | -55.1 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Aziyo Biologics
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
19.7 M | 25.3 M | 24.9 M | 24.6 M | 24.3 M | 20 M | 7.11 M | 8.76 M | 10.4 M | 12 M | 13.7 M | 15.5 M | 17.8 M | 17.8 M | 17.8 M | 17.8 M | 19.6 M | 19.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
85.7 M | 84.1 M | 74.5 M | 72.8 M | 73.9 M | 71.7 M | 54.2 M | 53.4 M | 53.6 M | 52 M | 54.7 M | 57.8 M | 62 M | 62 M | 62 M | 62 M | 55.4 M | 55.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | 5 K | 110 K | 251 K | 392 K | 533 K | 533 K | 533 K | 533 K | 650 K | 650 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-194 M | -166 M | -157 M | -146 M | -138 M | -133 M | -123 M | -113 M | -105 M | -96 M | -87.7 M | -85.3 M | -80.3 M | -80.3 M | -80.3 M | -80.3 M | -56.9 M | -56.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
35.4 M | 54.6 M | 52.3 M | 60.6 M | 68.8 M | 61 M | 52.9 M | 59.9 M | 67.2 M | 59.9 M | 69.7 M | 74.2 M | 82.8 M | 82.8 M | 82.8 M | 82.8 M | 44.8 M | 44.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
12.6 M | 14.5 M | 9.3 M | 11.8 M | 17 M | 8.1 M | 16.5 M | 22.2 M | 30.4 M | 22.5 M | 28.3 M | 30.4 M | 39.2 M | 39.2 M | 39.2 M | 39.2 M | 2.48 M | 2.48 M | - | - | 2.41 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-50.3 M | -29.5 M | -22.1 M | -12.2 M | -5.03 M | -10.7 M | -1.37 M | 6.56 M | 13.5 M | 7.86 M | 15 M | 16.4 M | 20.8 M | 20.8 M | 20.8 M | 20.8 M | -10.7 M | -10.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-50.3 M | -29.5 M | -22.1 M | -12.2 M | -5.03 M | -10.7 M | -1.37 M | 6.56 M | 13.5 M | 7.86 M | 15 M | 16.4 M | 20.8 M | 20.8 M | 20.8 M | 20.8 M | -55.1 M | -55.1 M | -49.3 M | - | -43.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency